Companies · Healthtech
San Francisco · CA, USA; LA, Nigeria · Healthtech · founded 2021 · https://infiuss.com
Diligence memoA one-page analyst read on Infiuss Health — recommendation, valuation, rhythm, risks.→Infiuss Health: limited disclosed financing to assess.
Synthesized from the figures below est. — every claim rests on a number shown on this page.
Infiuss Health is one of 2138 Healthtech companies tracked from San Francisco, CA, USA; LA, Nigeria, on record since 2021. By capital raised it ranks in the long tail (ahead of 8% of sector peers), and in the long tail by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%
operates a technology-led product inferred from public copy
Grounded in: “You are a venture analyst”
2 sided Marketplace for accelerating medical research
We are building the world's first community of patients eager to contribute to and advance medical research. Our patient community platform offers health management, patient support and patient health data aggregation. We offer researcher's and life science companies with the opportunity to connect with these patients for their medical research needs. They recruit real patients for clinical trials, for bio specimens sourcing and to obtaining real world patient data.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
No round amounts on record to chart.
No staged rounds to sequence.
Round size and date are reported; the stage label is inferred from round size. Valuation is modeled from stage benchmarks. Directional, not a quoted figure.
Not enough modeled valuation points to chart a trajectory.
Benchmarked against 2138 companies in Healthtech. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 8% of sector peers (real $). Modeled value above 8% of peers (estimate).
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| No rounds recorded. | |||||
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Infiuss Health is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| 10x | Healthtech | — | — | — | same sector |
| 1 Health Providence, Inc. | Healthtech | Pre-Seed | $175K | $1.9M | same sector |
| 4C Health Solutions, Inc. | Healthtech | Seed | $1.3M | $1.9M | same sector |
| Aatru Medical LLC | Healthtech | Seed | $5.7M | $335K | same sector |
| Acolyte Health Inc. | Healthtech | Seed | $2.1M | $1.2M | same sector |
| AcQumen Medical, Inc. | Healthtech | Pre-Seed | $341K | $758K | same sector |
| Adentris | Healthtech | — | — | — | same sector |
| Advanta Health Solutions, Inc. | Healthtech | Pre-Seed | $487K | $2.8M | same sector |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| Novelcare Empowering every doctor and every patient to participate in research | Healthtech | — | — | 76% |
| CareMessage Patient engagement for low-income populations | Healthtech | — | — | 75% |
| Probably Genetic Patient Intelligence Platform for Genetic Disease | Biotech | — | — | 74% |
| InpharmD We provide a curated, evidence- based answer to any clinical question. | — | — | — | 74% |
| Obento Health CRM Co-Pilot for Medtech Sales | Healthtech | — | — | 74% |
| Verse Medical Software platform for in-home healthcare | Healthtech | — | — | 74% |
| Miracle Accelerate clinical trials with real-time, actionable insights | Biotech | — | — | 74% |
| InQuery Intelligent Medical Record Reviews | Healthtech | — | — | 73% |
See where Infiuss Health sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Infiuss Health, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.